BIOCELL2025，Vol.49Issue(6)：P.991-1017,27.DOI:10.32604/biocell.2025.063486
Biomarkers and Underlying Pathways for Prediction of Response to Vedolizumab Therapy in Inflammatory Bowel Disease
Gloria Krajnc 1Lara Metlika 2Uroš Potocnik 3Boris Gole2
作者信息
- 1. Department for Science and Research,Maribor University Medical Centre,Ljubljanska ulica 5,Maribor,SI-2000,Slovenia
- 2. Centre for Human Molecular Genetics and Pharmacogenomics,Faculty of Medicine,University of Maribor,Taborska ulica 8,Maribor,SI-2000,Slovenia
- 3. Department for Science and Research,Maribor University Medical Centre,Ljubljanska ulica 5,Maribor,SI-2000,Slovenia Centre for Human Molecular Genetics and Pharmacogenomics,Faculty of Medicine,University of Maribor,Taborska ulica 8,Maribor,SI-2000,Slovenia Laboratory for Biochemistry,Molecular Biology and Genomics,Faculty of Chemistry and Chemical Engineering,University of Maribor,Smetanova ulica 17,Maribor,SI-2000,Slovenia
- 折叠
摘要
关键词
Inflammatory bowel disease/predictive biomarkers/anti-α4β7 integrins treatment/vedolizumab分类
医药卫生引用本文复制引用
Gloria Krajnc,Lara Metlika,Uroš Potocnik,Boris Gole..Biomarkers and Underlying Pathways for Prediction of Response to Vedolizumab Therapy in Inflammatory Bowel Disease[J].BIOCELL,2025,49(6):P.991-1017,27.基金项目
supported by the Slovenian Research and Innovation Agency(ARIS)—Young Researcher Program(contract no.104-04/TK–6811) （ARIS）
Research Core Funding P3-0427. （）
